(USNA) USANA Health Sciences - Ratings and Ratios
Nutritional Supplements, Skincare, Personal Care, Meal Replacements
USNA EPS (Earnings per Share)
USNA Revenue
Description: USNA USANA Health Sciences October 23, 2025
USANA Health Sciences, Inc. designs, manufactures, and markets science-based nutritional, personal-care, and skincare products across the Asia-Pacific, the Americas, and Europe, positioning itself as a global wellness brand.
The business operates through two primary segments: a traditional Direct-Selling channel that relies on independent associates, and the Hiya Direct-To-Consumer segment, which emphasizes e-commerce and subscription models.
Its product portfolio includes USANA nutritional optimizers (targeting cardiovascular, skeletal, and digestive health), Essentials/CellSentials vitamin-mineral lines for children 13 months and up, meal-replacement shakes and snack bars for weight-management and energy, and the Celavive skincare regimen tailored to diverse skin types and ethnicities.
Products reach consumers via retail outlets, a subscription service, direct-selling associate networks, and online platforms, providing multiple touchpoints for customer acquisition and retention.
USANA leverages research collaborations with Beijing University of Chinese Medicine and the National Sports Training Bureau to bolster product credibility and explore novel formulations.
In FY 2023 the company generated approximately $2.3 billion in revenue, up 8 % year-over-year, with an operating margin near 10 %; its Direct-Selling segment contributed roughly 70 % of sales, reflecting the sector’s resilience amid a projected 5 % CAGR for global direct-selling revenues through 2028. Additionally, the growing consumer preference for scientifically validated supplements and clean-label personal-care products serves as a tailwind for USANA’s growth trajectory.
For a deeper, data-driven assessment of USANA’s valuation metrics and risk profile, you may find ValueRay’s analytical tools worth exploring.
USNA Stock Overview
| Market Cap in USD | 386m |
| Sub-Industry | Personal Care Products |
| IPO / Inception | 1996-07-25 |
USNA Stock Ratings
| Growth Rating | -82.6% |
| Fundamental | 63.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -58.6% |
| Analyst Rating | 3.0 of 5 |
USNA Dividends
Currently no dividends paidUSNA Growth Ratios
| Growth Correlation 3m | -90.9% |
| Growth Correlation 12m | -65.7% |
| Growth Correlation 5y | -94.7% |
| CAGR 5y | -28.57% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.40 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.89 |
| Sharpe Ratio 12m | -1.47 |
| Alpha | -63.33 |
| Beta | 0.605 |
| Volatility | 51.08% |
| Current Volume | 255k |
| Average Volume 20d | 298.7k |
| Stop Loss | 18 (-5.9%) |
| Signal | -0.45 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (17.0m TTM) > 0 and > 6% of Revenue (6% = 54.8m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA -1.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 15.93% (prev 39.03%; Δ -23.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 63.0m > Net Income 17.0m (YES >=105%, WARN >=100%) |
| Net Debt (-145.3m) to EBITDA (83.9m) ratio: -1.73 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (18.3m) change vs 12m ago -4.14% (target <= -2.0% for YES) |
| Gross Margin 79.18% (prev 80.86%; Δ -1.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 130.6% (prev 128.4%; Δ 2.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 57.34 (EBITDA TTM 83.9m / Interest Expense TTM 848.0k) >= 6 (WARN >= 3) |
Altman Z'' 7.23
| (A) 0.20 = (Total Current Assets 264.1m - Total Current Liabilities 118.7m) / Total Assets 726.6m |
| (B) 0.66 = Retained Earnings (Balance) 478.9m / Total Assets 726.6m |
| (C) 0.07 = EBIT TTM 48.6m / Avg Total Assets 698.9m |
| (D) 3.15 = Book Value of Equity 456.3m / Total Liabilities 145.0m |
| Total Rating: 7.23 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.99
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 18.19% = 5.0 |
| 3. FCF Margin 5.59% = 1.40 |
| 4. Debt/Equity 0.07 = 2.50 |
| 5. Debt/Ebitda -1.73 = 2.50 |
| 6. ROIC - WACC (= 3.03)% = 3.79 |
| 7. RoE 3.21% = 0.27 |
| 8. Rev. Trend -22.33% = -1.67 |
| 9. EPS Trend -55.71% = -2.79 |
What is the price of USNA shares?
Over the past week, the price has changed by -9.55%, over one month by -27.35%, over three months by -34.01% and over the past year by -52.80%.
Is USANA Health Sciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of USNA is around 12.38 USD . This means that USNA is currently overvalued and has a potential downside of -35.28%.
Is USNA a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the USNA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 39 | 103.9% |
| Analysts Target Price | 39 | 103.9% |
| ValueRay Target Price | 13.7 | -28.5% |
USNA Fundamental Data Overview November 02, 2025
P/E Trailing = 11.75
P/E Forward = 11.919
P/S = 0.4234
P/B = 0.9441
P/EG = 0.9381
Beta = 0.605
Revenue TTM = 912.7m USD
EBIT TTM = 48.6m USD
EBITDA TTM = 83.9m USD
Long Term Debt = 6.01m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 29.0m USD (from shortTermDebt, last fiscal year)
Debt = 39.2m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -145.3m USD (from netDebt column, last quarter)
Enterprise Value = 280.3m USD (386.4m + Debt 39.2m - CCE 145.3m)
Interest Coverage Ratio = 57.34 (Ebit TTM 48.6m / Interest Expense TTM 848.0k)
FCF Yield = 18.19% (FCF TTM 51.0m / Enterprise Value 280.3m)
FCF Margin = 5.59% (FCF TTM 51.0m / Revenue TTM 912.7m)
Net Margin = 1.86% (Net Income TTM 17.0m / Revenue TTM 912.7m)
Gross Margin = 79.18% ((Revenue TTM 912.7m - Cost of Revenue TTM 190.0m) / Revenue TTM)
Gross Margin QoQ = 77.15% (prev 78.72%)
Tobins Q-Ratio = 0.39 (Enterprise Value 280.3m / Total Assets 726.6m)
Interest Expense / Debt = 0.12% (Interest Expense 49.0k / Debt 39.2m)
Taxrate = 471.3% (out of range, set to none) (8.46m / 1.79m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.23 (Total Current Assets 264.1m / Total Current Liabilities 118.7m)
Debt / Equity = 0.07 (Debt 39.2m / totalStockholderEquity, last quarter 528.1m)
Debt / EBITDA = -1.73 (Net Debt -145.3m / EBITDA 83.9m)
Debt / FCF = -2.85 (Net Debt -145.3m / FCF TTM 51.0m)
Total Stockholder Equity = 530.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.34% (Net Income 17.0m / Total Assets 726.6m)
RoE = 3.21% (Net Income TTM 17.0m / Total Stockholder Equity 530.3m)
RoCE = 9.07% (EBIT 48.6m / Capital Employed (Equity 530.3m + L.T.Debt 6.01m))
RoIC = 10.51% (EBIT 48.6m / (Assets 726.6m - Curr.Liab 118.7m - Cash 145.3m))
WACC = 7.48% (E(386.4m)/V(425.7m) * Re(8.24%) + (debt cost/tax rate unavailable))
Discount Rate = 8.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.52%
[DCF Debug] Terminal Value 75.30% ; FCFE base≈54.3m ; Y1≈47.2m ; Y5≈37.8m
Fair Price DCF = 36.36 (DCF Value 664.4m / Shares Outstanding 18.3m; 5y FCF grow -16.00% → 3.0% )
EPS Correlation: -55.71 | EPS CAGR: -60.26% | SUE: -4.0 | # QB: 0
Revenue Correlation: -22.33 | Revenue CAGR: -2.33% | SUE: -0.03 | # QB: 0
Additional Sources for USNA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle